Skip to main
HQY

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 7%

Bulls say

HealthEquity is a promising company due to its strong HSA business and potential for market expansion. Despite a lowered price target, it is still projected to have a 40% upside, supported by its 20.7% increase in gross profit and improved gross margin. With its solid adjusted EBITDA and net income, along with a focus on becoming a leader in health-tech and services, HealthEquity is expected to surpass expectations and outperform in the future. The company also showed strong third quarter results with growth in revenue and gross margin, as well as significant growth in custodial revenue and client-held funds. Overall, HealthEquity is a financially stable company with a positive financial outlook, making it a strong choice for investors.

Bears say

HealthEquity is facing increasing competition in the healthcare savings industry and has experienced lower average service fees per account. While they have managed to decrease service costs through technological investments, it is not enough to offset the decrease in fees, leading to a decrease in gross margins. Additionally, with a high Long-term debt of $957.4 million, the company may struggle to generate enough cash flow to pay down its debt over time.

HealthEquity (HQY) has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 14 analysts, HealthEquity (HQY) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $115.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $115.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.